|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Tuesday, March 17, 2020 |
|
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
| 新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社（NYSE American: NNVC） （以下「当社」）は、COVID-19を引き起こす現在の新型コロナウイルス（SARS-CoV-2）の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
|
NanoViricides公司冠狀病毒藥物開發更新 |
| NanoViricides公司（美國紐約證券交易所交易代碼NNVC）（公司）是基於新型納米藥學平台（公司）開發高效抗病毒治療方法的領先公司，目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發，現提供其工作相關更新。 more info >> |
|
|
NanoViricides公司冠状病毒药物开发更新 |
| NanoViricides公司（美国纽约证券交易所交易代码 NNVC）（公司）是基于新型纳米药学平台（公司）开发高效抗病毒治疗方法的领先公司，目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发，现提供其工作相关更新。 more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
雲知聲港股招股：衝刺港股「AGI第一股」
Jun 25, 2025 00:00 HKT/SGT
|
|
|
35th HKTDC Hong Kong Book Fair opens on 16 July
Jun 24, 2025 23:38 HKT/SGT
|
|
|
35th HKTDC Hong Kong Book Fair opens on 16 July
Jun 24, 2025 20:03: JST
|
|
|
Founders Metals Hits 22.5 m of 11.88 g/t Gold in New Discovery at Maria Geralda
Jun 24, 2025 19:39 HKT/SGT
|
|
|
超900倍認購創紀錄！海天味業港股上市創紀錄 開啟全球化新篇章
Jun 24, 2025 18:49 HKT/SGT
|
|
|
超900倍认购创纪录！海天味业港股上市创纪录 开启全球化新篇章
Jun 24, 2025 18:39 HKT/SGT
|
|
|
云知声港股招股：冲刺港股AGI第一股
Jun 24, 2025 14:05 HKT/SGT
|
|
|
富士通、誰もが安心して暮らせる仮設住宅の実現に向けて、ミリ波レーダを活用した高齢者見守りの実証実験を実施
Jun 24, 2025 10:30: JST
|
|
|
The Executive Centre Further Expands in Tokyo with New Centres at JP Tower Level 11 and GranTokyo South Tower
Jun 24, 2025 10:00 HKT/SGT
|
|
|
新冠疫情多地爆發 楷和醫療求診數量增
Jun 24, 2025 08:04 HKT/SGT
|
|
|
Two new microalgae genera discovered in Indonesian waters
Jun 24, 2025 07:00 HKT/SGT
|
|
|
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
Jun 23, 2025 21:00 HKT/SGT
|
|
|
Executive Appointments in Connection with the Establishment of NESIC Holdings
Jun 23, 2025 19:22 JST
|
|
|
雲知聲在港招股 AGI獨角獸進入IPO衝刺階段
Jun 23, 2025 17:20 HKT/SGT
|
|
|
云知声在港招股 AGI独角兽进入IPO冲刺阶段
Jun 23, 2025 17:20 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
